09.08.2017: Novel Tool for Investigating Therapy Resistance of Cancer Cells
In this study, murine mammary carcinoma cells (H8N8 and H8N8 T3.2) were used on the CardioExcyte 96 to measure toxicity of cyclophosphamide, doxorubicin and 5-fluouracil (CAF)
Because of the risk of recurrence in the remaining breast tissue after removal of the primary tumor, adjuvant therapies in form of radiation therapy or/and chemotherapy are used to ensure that remaining microscopic disease will be eradicated and to help to extend patients’ survival time, by lessening the chance of local recurrence. *One of the standard clinical regimens is a combination of cyclophosphamide, adriamycin (doxorubicin) and 5-fluouracil (CAF) that is given for four months. Despite initially successful multimodal therapy, tumor recurrence remains a major cause of the morbidity and mortality in cancer patients . Moreover, chemotherapy resistance is a well-known challenge in successfully treating cancer patients . The high incidence of breast cancer and the high mortality of the disease ask for better treatment options.
Methods / Results
In this study, murine mammary carcinoma cells (H8N8 and H8N8 T3.2) were used on the CardioExcyte 96 and monitored over a time period of 500 h. The CardioExcyte 96 is a device developed for investigating iPS-derived cardiomyocytes by recording impedance changes with 1 ms time resolution and has proven to be perfectly suited for assays on multiple other adherent cells. Here, changes in impedance, and therefore confluency, were used as a measure of toxicity. Intrinsic (dose-dependent) effects of the standard clinical treatment regimen cyclophosphamide, doxorubicin and 5-fluouracil (CAF) could be identified consistent with other methods of live cell analysis systems. Therefore, the CardioExcyte 96 in combination with murine mammary carcinoma cells provides a novel tool for investigating therapy resistance of cancer cells in vitro.
The full application note is available soon. Stay tuned for updated information or contact me at firstname.lastname@example.org, I´m happy to provide more details and answer any questions.
1. Mitra A, Mishra L, Li S: EMT, CTCs and CSCs in tumor relapse and drug- resistance. Oncotarget 2015, 6(13):10697-10711.
2. Gatti L, Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005, 111:127-148.